Exhibit 99.1 HUTCHMED Reports 2022 Interim Results and Provides Business Updates Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA ® and ORPATHYS® growth First presentation of SAVANNAH data showing 52% response rate and 9.6 month duration of response in 2L+ post-TAGRISSO® NSCLC1 patients with high MET 2levels and no prior chemotherapy Initiated six new trials thus far in 2022 with a further six starting, including with five new drug candidates FRESCO-2 Phase III, our first glob ...

Revenue Growth - The comprehensive revenue from the oncology/immunology business increased nearly 4 times to $119.6 million in 2021, with this trend continuing into 2022 [15]. - Total revenue for 2021 increased by 56% to $356.1 million, driven by the commercialization of three self-developed oncology drugs [18]. - Other business revenue grew by 20% (CER: 13%) to $236.5 million in 2021, compared to $197.8 million in 2020 [31]. - The oncology/immunology business revenue for 2021 reached $119.6 million, a 296% increase compared to $30.2 million in 2020, aligning with the revenue guidance of $110 million to $130 million [18]. - The sales of Aiyoute® (Fruquintinib) in China grew by 111% to $71 million in 2021, reflecting strong management performance in medical communication and marketing [18]. - The sales of Vorasatinib® (Savolitinib) reached $15.9 million in 2021, as it became the first selective MET inhibitor in China, quickly gaining market recognition [18]. - The sales of Sunitinib® (Sofitinib) was launched in 2021 for treating neuroendocrine tumors, generating sales of $11.6 million, marking a promising start in the self-pay market [18]. Clinical Development - There are currently over 45 clinical studies ongoing globally, with seven innovative drug candidates undergoing clinical development outside of China [12][15]. - The company has initiated four Phase III studies and one Phase II study for the drug Vorasertib, which received its first approval in 2021, triggering a milestone payment of $40 million [15]. - The NDA application for Surufatinib for the treatment of advanced neuroendocrine tumors is in the late stages of registration review in the EU [15]. - The company has a pipeline of 12 innovative molecular drugs, with three already approved and successfully launched [11][13]. - In 2021, the company initiated several key clinical studies for its drug Savolitinib, including a global Phase III study (NCT05043090) in October for treating MET-driven unresectable and locally advanced or metastatic papillary renal cell carcinoma [23]. - The company plans to initiate a Phase III study (SURTORI-02) in China for the combination therapy of Savolitinib and Tuoyi® for esophageal cancer in the second half of 2022 [24]. - The company has initiated multiple Phase II studies for Furmonertinib in combination with other therapies for advanced or metastatic cancers, including colorectal and gastric cancers [24]. Financial Position - The company has over $1 billion in cash and plans to divest non-core assets to support its strategic initiatives [16]. - Cash and cash equivalents and short-term investments totaled $1.0117 billion as of December 31, 2021, compared to $435.2 million at the end of 2020 [38]. - The company reported a net loss attributable to shareholders of $194.6 million in 2021, compared to a net loss of $125.7 million in 2020, reflecting a 55.0% increase in losses [42]. - The total operating expenses for 2021 were $684.4 million, up from $424.6 million in 2020, indicating a 61.1% increase [42]. - The company’s total assets grew to $1.373 billion in 2021, compared to $724.1 million in 2020, a 89.8% increase [41]. Leadership Changes - The new CEO, Dr. Su Weiguo, has been appointed as part of the succession planning following the retirement of the previous CEO, Mr. He Jun [13][14]. - The company is expanding its leadership team with experienced professionals from the pharmaceutical industry, including former executives from Gilead Sciences and Takeda Pharmaceuticals [142][143]. Research and Development - R&D expenses increased to $299.1 million in 2021 from $174.8 million in 2020, marking a 70.9% growth due to the expansion of innovative oncology drug candidates [39]. - The company continues to prioritize employee development and community engagement through various training programs and initiatives [131]. - The company is focused on enhancing its corporate governance practices, with members holding senior positions in professional accounting and governance bodies [144]. Strategic Partnerships - The company has established a partnership with Hain Celestial for the marketing, distribution, and sales of its products, with pricing based on standard costs plus a profit margin [172]. - The company collaborates with Eli Lilly for fuzuloparib's rights outside of China, enhancing its market reach [64]. Sustainability and Governance - The company aims to enhance its sustainability practices and has established a sustainability committee at the board level [35]. - The company is committed to sustainable development, as indicated by the presence of a dedicated committee chaired by a board member [141]. - The company has a strong emphasis on research and development, particularly in innovative therapies for cancer [143][145]. Shareholder Information - The company reported a total shareholding of 332,574,650 shares, representing approximately 38.46% ownership by CK Hutchison Global Investments Limited [180]. - The company has adopted a share trading code for directors to disclose their interests and holdings [148]. - The company has a stock option plan adopted in 2015, which remains in effect [184].

HUTCHMED (China) Limited (NASDAQ:HCM) Q4 2021 Earnings Conference Call March 3, 2022 8:00 AM ET Company Participants Christian Hogg - Chief Executive Officer Hong Chen - Senior Vice President and Chief Commercial Officer, China Weiguo Su - Executive Director and Chief Scientific Officer Marek Kania - Executive Vice President, Managing Director and Chief Medical Officer, International Mark Lee - Senior Vice President, Corporate Finance & Development Johnny Cheng - Executive Director and Chief Financial Offic ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark one) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 co ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR Date of event requiring this shell comp ...

Exhibit 99.1 HUTCHMED Reports 2021 Full Year Results and Provides Business Updates Oncology/Immunology revenues up 296% to $119.6 million, due to ELUNATE growth and the 2021 launches of SULANDA and ORPATHYS; Positive SAVANNAH, CALYPSO and VIKTORY studies triggered five registration studies on ORPATHYS in lung cancer, kidney and gastric cancer during 2021; Broad late-stage development program – currently enrolling 13 registration studies on 6 assets – with enrollment on the 691 patient FRESCO-2 global Phase ...

HUTCHMED (China) Limited (NASDAQ:HCM) Q2 2021 Earnings Conference Call July 28, 2021 8:00 AM ET Company Participants Christian Hogg - Chief Executive Officer Mark Lee - Senior Vice President Corporate Finance & Development Wei-Guo Su - Chief Scientific Officer Marek Kania - Managing Director for HUTCHMED International & Chief Medical Officer Conference Call Participants Alec Stranahan - Bank of America Louise Chen - Cantor David Ng - Macquarie Paul Choi - Goldman Sachs Mike Mitchell - Panmure Gordon Operato ...